Recent Company News

• 12:09 PM ET May 27, 2026
  

  Transcript Intelligence: Molecular Partners at TD Cowen Oncology Innovation Summit

• 04:22 AM ET Apr 20, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 04:03 PM ET May 12, 2026
  

  Molecular Partners reports financial results and highlights for Q1 2026 (CHF 3.14, 0.00)

• 01:05 AM ET May 04, 2026
  

  Molecular Partners to present new data on MP0712 at forthcoming scientific conferences (CHF 3.21, 0.00)

• 07:02 AM ET May 01, 2026
  

  Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling (CHF 3.21, 0.00)

• 04:48 PM ET Apr 19, 2026
  

  Molecular Partners presents three posters at AACR 2026, new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 (CHF 3.27, 0.00)

• 02:35 PM ET Apr 17, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 19-Apr

• 02:16 PM ET Apr 10, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 12-Apr